Jeffrey N. Miner

Prior to founding Viscient, Dr. Miner held research leadership positions at Ardea Biosciences, a member of the Astrazeneca group, and Ligand Pharmaceuticals. His responsibilities at Ardea covered the Biology program as it relates to the discovery, preclinical, translational, and clinical development. He was Head of Molecular and Cellular Biology at Ligand Pharmaceuticals. He is a Faculty Advisor and Molecular Biology Institute Associate at San Diego State University and is a Scientific Advisory Board Member for ARTA Bioscience. His Ph.D. graduate work was conducted in Virology at Oregon State University with a post-doctoral fellowship at the University of California San Francisco in glucocorticoid gene regulation. He has drug discovery experience in the Inflammation, Oncology, Endocrine, and Cardiovascular drug discovery therapeutic areas and his work has led to or enhanced the development of multiple marketed compounds. His target areas of expertise include Nuclear Receptors, Kinases, and Transporters. He has published over 60 peer-reviewed articles and book chapters and is an inventor on multiple patents.